Evommune, Inc. (EVMN) shares are cooling off Thursday after Wednesday's explosive 70% rally, a classic case of investors locking in gains after big news.

The catalyst? On Tuesday, the biotech company unveiled positive results from its Phase 2a trial testing EVO301 as a treatment for moderate-to-severe atopic dermatitis, better known as eczema. The data was strong enough to send the stock rocketing, and now the question is whether this early success can translate into a blockbuster drug.

Strong Efficacy Signal in Eczema Trial

The trial results showed EVO301 delivered a 33% placebo-adjusted improvement in the Eczema Area and Severity Index (EASI) at the 12-week mark. Perhaps more impressively, 23% of patients achieved a score of 0 or 1 on the Investigator's Global Assessment for Atopic Dermatitis, which essentially means their skin was clear or nearly clear.

Evommune now plans to advance into a Phase 2b dose-ranging study using a subcutaneous formulation of EVO301. The company is also eyeing additional indications beyond eczema, including ulcerative colitis, which could significantly expand the drug's commercial opportunity.

Analysts See Billion-Dollar Potential

William Blair jumped on the data Tuesday, writing, "We believe the results provide clear proof of concept for EVO301 in AD, an asset that we believe had little valuation reflected in Evommune's share price..."

Analyst Matt Phipps noted that full details from the Phase 2a study will be presented at an upcoming medical meeting, and additional clarity on the subcutaneous doses moving into Phase 2b will help define EVO301's product profile and positioning in the substantial atopic dermatitis market.

The firm raised its probability of success for EVO301 to 51% from 29% and boosted its 2035 sales estimate to $1 billion from $760 million. "We believe this could still prove conservative, particularly if efficacy is demonstrated in other diseases, namely ulcerative colitis," Phipps added.

Technical Picture Shows Mixed Signals

Despite the recent pullback, the stock is trading 38.7% above its 20-day simple moving average and 45.3% above its 50-day SMA, indicating strong momentum from the trial results. However, shares are still down 16.02% over the past year and remain closer to their 52-week lows than highs.

The RSI sits at 69.29, considered neutral territory, while the MACD is above its signal line, suggesting bullish momentum. The combination points to mixed near-term direction after the recent volatility.

• Key Resistance: $33.00
• Key Support: $25.00

Wall Street Weighs In

The stock carries a Strong Buy rating with an average price target of $44.17. Recent analyst actions include:

• HC Wainwright & Co.: Buy rating with price target raised to $65.00 (Feb. 10)
• Oppenheimer: Initiated coverage with Outperform rating and $42.00 target (Jan. 22)
• Raymond James: Initiated coverage with Strong Buy rating and $40.00 target (Jan. 8)

EVMN Price Action: Evommune shares were down 3.62% at $27.43 at the time of publication Thursday.